Hester Biosciences Limited reported a consolidated net profit of ₹967.32M for Q1FY27, a 459% year-on-year increase from ₹172.96M in Q1FY26. The surge was primarily driven by an exceptional accounting gain of ₹853.49M following the amendment of a loan with the Gates Foundation at its subsidiary, Hester Biosciences Africa Limited (HBAL). While headline profits soared, core operational metrics showed mixed results, with standalone revenue rising 14% while consolidated revenue declined 8% due to lower contributions from Nepal and Africa operations.

Consolidated Financial Performance

The consolidated results reflect the substantial impact of the debt restructuring. The outstanding principal of the HBAL loan was reduced from USD 12.00 million to USD 5.00 million, with all accrued interest waived and the revised loan made interest-free. Under Ind AS 109, this modification was treated as an extinguishment of the original liability, resulting in the ₹853.49M gain recognized as an exceptional item.

Excluding the exceptional item, the profit before tax stood at ₹163.33M, down from ₹201.87M in the corresponding quarter last year. Consolidated EBITDA remained flat at ₹228M year-on-year, while the EBITDA margin improved to 29.50% from 27%, reflecting modest operational efficiency gains at the consolidated level. This decline in underlying pre-tax earnings highlights the pressure on core profitability despite the overall boost from the one-time gain.

Standalone Operational Highlights

On a standalone basis, Hester demonstrated stronger operational execution, particularly in its Poultry Healthcare division. Standalone revenue from operations increased by 14% to ₹726.60M from ₹634.90M in Q1FY26. The Poultry Healthcare division saw a robust 48% revenue growth to ₹617.69M, driven by higher institutional business and deeper market penetration. In contrast, the Animal Healthcare division experienced a 50% revenue decline to ₹108.44M, attributed to delays in government-led immunisation programme tender executions rather than demand shifts.

Standalone net profit after tax (PAT) rose sharply by 88% to ₹147.11M from ₹78.38M. Standalone EBITDA expanded by 95% to ₹260.34M, with margins improving to 36% from 21% in the prior year quarter. Gross profit margins also widened to 78% from 69%, supported by a favourable product mix and operational efficiencies.

Segment Analysis

The divergence between standalone and consolidated performance is evident in the segment data. While domestic poultry operations thrived, international segments faced headwinds. Consolidated revenues were lower largely due to variability in institutional order timing in Nepal and ongoing market development efforts in Africa. The Animal Healthcare segment's standalone result turned negative at -₹8.47M compared to ₹35.25M in Q1FY26, reflecting the timing impact of government tenders.

What the Numbers Show

The financial results underscore a bifurcated performance narrative for Hester Biosciences. Operationally, the company is executing well in its core domestic poultry business, with significant margin expansion and revenue growth. However, the reliance on government tenders in animal healthcare and volatile international markets continues to pose challenges. The massive exceptional gain masks a decline in underlying pre-tax profitability, suggesting that while the balance sheet has been strengthened through debt relief, operational cash generation remains sensitive to external regulatory and market timing factors.

Hester Biosciences Limited has scheduled an earnings conference call for Thursday, July 30, 2026, at 2:00 p.m. IST to discuss its financial results for the quarter ended June 30, 2026. This disclosure serves as a formal intimation to shareholders and market participants regarding the upcoming investor interaction, which is a standard regulatory requirement following the announcement of quarterly financial outcomes. The company filed the notice with both BSE Limited and the National Stock Exchange of India Limited on July 25, 2026, citing compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The filing was signed by Vinod Mali, Company Secretary & Compliance Officer, confirming procedural adherence to listing norms. ICICI Securities is acting as the coordinator for the event. Investors can join the teleconference using the Diamond Pass registration link provided in the official enclosure. For logistical clarifications, contact details have been provided for Jaideep Goswami, Head of Equities, along with other designated coordinators including Abdulkader Puranwala, Rushad Kapadia, Seema Sehgal, and Minali Ginwala.

Key Participants

The conference call will be led by senior management executives who will address investor queries regarding the Q1FY27 performance. The key participants include:

What This Means for Investors

While the filing itself does not disclose specific financial metrics such as net profit or revenue figures, the scheduling of the call indicates that Hester Biosciences Limited has completed its internal audit and reporting process for Q1FY27. Investors should prepare for detailed discussions on operational performance, margin trends, and future guidance during the live session. The absence of immediate financial data in this notice means that all material quantitative insights will be revealed during the July 30 interaction.